AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30079582
Drug: Self-administered questionnaires
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered questionnaires (MASRI < 80%)
Trial: 30081223
Drug: EG Scan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EG Scan II (transnasal capsule endoscope)
Trial: 30081838
Drug: Ongoing treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing treatment with zidovudine (76% of children, median duration 48 months (26-74))
Trial: 30081838
Drug: Previous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous treatment with stavudine (18% of children, median treatment duration 8 months (5-25))
Trial: 30081838
Drug: Ongoing treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing treatment with lopinavir/ritonavir (27% of children, median duration 49 months (23-59))
Trial: 30081846
Drug: Decision aid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decision aid administered prior to specialist consultation
Trial: 30081846
Drug: Decision aid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decision aid administered within the consultation
Trial: 30081846
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both decision aids
Trial: 30081867
Drug: Quizartinib 135
RxNorm normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Quizartinib 135 mg/day
Trial: 30081867
Drug: Quizartinib 90
RxNorm normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Quizartinib 90 mg/day
Trial: 30081867
Drug: Quizartinib (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quizartinib (both doses)
Trial: 30081937
Drug: Assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of smoking, exercise habits, BMI, trust in treatment, and satisfaction with care
Trial: 30082340
Drug: SH003 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SH003 (1 to 4 tablets, three times a day for 3 weeks)
Trial: 30082340
Drug: SH003 (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SH003 (dose escalation)
Trial: 30082349
Drug: Sorbitol syrup
RxNorm normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorbitol syrup (control)
Trial: 30082474
Drug: Single-agent options
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent options
Trial: 30082475
Drug: Alisertib 50
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib 50 mg b.i.d. plus rituximab 375 mg/m2
Trial: 30082475
Drug: Alisertib 40
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib 40 mg b.i.d. plus rituximab and vincristine
Trial: 30083405
Drug: Treatment modality
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment modality and compliance
Trial: 30084702
Drug: 10-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-valent pneumococcal conjugate vaccine
Trial: 30084943
Drug: Efavirenz 400
RxNorm normalized name: efavirenz 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz 400 mg (EFV400) coadministered with Isoniazid (INH) and Rifampicin (RIF) after 4 weeks (PK2)
Trial: 30084943
Drug: Efavirenz 400
RxNorm normalized name: efavirenz 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz 400 mg (EFV400) coadministered with Isoniazid (INH) and Rifampicin (RIF) after 12 weeks (PK3)
Trial: 30084943
Drug: Efavirenz 400
RxNorm normalized name: efavirenz 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz 400 mg (EFV400) without coadministration (PK1)
Trial: 30085139
Drug: 2-dose schedule
RxNorm normalized name: hepatitis A vaccine (inactivated) strain HM175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose schedule of bivalent HPV vaccine (bHPV)
Trial: 30085139
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of either bivalent HPV vaccine (bHPV) or quadrivalent HPV vaccine (qHPV)
Trial: 30085139
Drug: 3-dose schedule
RxNorm normalized name: hepatitis A vaccine, pediatric/adolescent dosage, 3 dose schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dose schedule of bivalent HPV vaccine (bHPV)
Trial: 30086261
Drug: Small-bowel capsule
RxNorm normalized name: Smallpox (Vaccinia) Vaccine, Live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-bowel capsule endoscopy (CE)
Trial: 30086777
Drug: Ruxolitinib 10
RxNorm normalized name: ruxolitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 10 mg BID, with incremental increases of 5 mg BID at weeks 12 and 18 (maximum 20 mg BID)
Trial: 30086778
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment arm (paper-based hypertension treatment guidelines)
Trial: 30087028
Drug: Momelotinib 150
RxNorm normalized name: momelotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Momelotinib 150 mg twice daily combined with trametinib 1.0 mg once daily
Trial: 30087093
Drug: Usual clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual clinical treatment (UCT) group
Trial: 30087197
Drug: Rescue medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue medication availability in the home
Trial: 30087197
Drug: Medication readiness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication readiness criteria
Trial: 30087197
Drug: Controller medication
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controller medication availability in the home
Trial: 30087197
Drug: Controller medication
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controller medication readiness criteria
Trial: 30444686
Drug: Four cycles
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four cycles of chemotherapy
Trial: 30088048
Drug: Afatinib 20
RxNorm normalized name: afatinib 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 20 mg/day with Carboplatin AUC6 (A/C)
Trial: 30088048
Drug: Afatinib 40
RxNorm normalized name: afatinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 40 mg/day with Carboplatin AUC6 (A/C)
Trial: 30088048
Drug: Afatinib 20
RxNorm normalized name: afatinib 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 20 mg/day with Carboplatin AUC6 and Paclitaxel 175 mg/m2 (A/C/P)
Trial: 30088198
Drug: HBsAg-based recombinant
RxNorm normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBsAg-based recombinant vaccine administered every 8 weeks for 48 weeks (seven doses)
Trial: 30088336
Drug: Low-energy diet
RxNorm normalized name: Low-energy diets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy diet (LED) 3.4 MJ/810 kcal daily for 8 weeks
Trial: 30088802
Drug: Tidal breathing
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal breathing measurements before and after inhaled albuterol (1 week before anticipated hospital discharge)
Trial: 30088802
Drug: Bronchodilator response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bronchodilator response
Trial: 30089406
Drug: Sodium <20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium <20 mmol/L
Trial: 30089406
Drug: Sodium >20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium >20 mmol/L
Trial: 30089457
Drug: Hypo-fractionated radiotherapy
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypo-fractionated radiotherapy at 40.0 Gy/2.5 Gy with concurrent S-1 at 80 mg/m2
Trial: 30089523
Drug: Pharmacist-led medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led medication use review
Trial: 30091207
Drug: Intense Pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense Pulsed Light (IPL) therapy followed by Non-Ablative Fractionated Laser (NAFL) treatment
Trial: 30092965
Drug: Anthracycline therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracycline therapy (Doxorubicin)
Trial: 30093531
Drug: Thioridazine (TDZ)
RxNorm normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thioridazine (TDZ) 25 mg every 6 hours for 21 days
Trial: 30093531
Drug: Thioridazine (TDZ)
RxNorm normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thioridazine (TDZ) 50 mg every 6 hours for 21 days
Trial: 30093531
Drug: Thioridazine (TDZ)
RxNorm normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thioridazine (TDZ) 100 mg every 6 hours for 21 days
Trial: 30093866
Drug: Mediterranean diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean diet with vitamin D (10 μg/day)
Trial: 30094070
Drug: MAGE-A3 immunotherapeutic
RxNorm normalized name: Kitasamycin A3
DrugBank: Josamycin (DB01321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAGE-A3 immunotherapeutic (4-cycle schedule, ≤24 doses)
Trial: 30095576
Drug: Increased vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased vitamin D dosage according to NACFF guidelines
Trial: 30095603
Drug: XEN gel
RxNorm normalized name: XEN-2174
DrugBank: XEN-2174 (DB05012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XEN gel implant surgery (combined XEN+cataract surgery or standalone XEN surgery)
Trial: 30096071
Drug: Yellow fever
RxNorm normalized name: yellow fever live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow fever vaccine (YF-17D strain)
Trial: 30096144
Drug: Treatment Self-Regulation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Self-Regulation Questionnaire (TSRQ)
Trial: 30098602
Drug: Transfused RBC
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfused RBC characteristics (irradiation and metabolism)
Trial: 30098707
Drug: Rivaroxaban 15mg
RxNorm normalized name: RIVAROXABAN 15MG TAB
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 15mg administered twice daily for 90 days
Trial: 30099150
Drug: Intensive mobilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive mobilization under analgesic gas (equimolar mixture of oxygen and nitrous oxide)
Trial: 30099150
Drug: Intensive mobilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive mobilization under placebo gas (sham gas administration)
Trial: 30099150
Drug: Intensive mobilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive mobilization under analgesic gas
Trial: 30099350
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) treatment for eight weeks
Trial: 30099396
Drug: Laparoscopic distal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic distal gastrectomy (LDG) after neoadjuvant chemotherapy
Trial: 30099396
Drug: Open distal
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open distal gastrectomy (ODG) after neoadjuvant chemotherapy
Trial: 30099397
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) - intravenous infusion of 10 mL (1 g) immediately followed by three identical infusions over 8 hours (total dose of 4 g over 24 hours)
Trial: 30099397
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) - intravenous infusion of 40 mL over 24 hours
Trial: 30099641
Drug: Denosumab administration
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab administration
Trial: 30099818
Drug: Sym004 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sym004 6 mg/kg/wk
Trial: 30099818
Drug: Sym004 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sym004 9 mg/kg loading/6 mg/kg/wk
Trial: 30099818
Drug: Sym004 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sym004 12 mg/kg/wk
Trial: 30099818
Drug: Sym004 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sym004 18 mg/kg biweekly
Trial: 30099818
Drug: Sym004 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sym004 at the dose recommended from Part A (12 mg/kg/wk) in Part B
Trial: 30101351
Drug: Dietary intake
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary intake of one-carbon metabolism nutrients
Trial: 30101387
Drug: BGJ398 daily
RxNorm normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BGJ398 daily 3 weeks on, 1 week off (dose range: 25 - 75 mg)
Trial: 30101387
Drug: BGJ398 daily
RxNorm normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BGJ398 daily 1 week on, 3 weeks off (dose range: 75 - 100 mg)
Trial: 30101387
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of BGJ398 and imatinib
Trial: 30101412
Drug: Acid suppression
RxNorm normalized name: Buckley's Cough Suppressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid suppression therapy
Trial: 30102205
Drug: Intensity Modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity Modulated Radiation Therapy (IMRT) followed by gemcitabine, dexamethasone, and cisplatin (GDP)
Trial: 30102789
Drug: Teriparatide treatment
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teriparatide treatment for 2 years
Trial: 30103979
Drug: Guideline-directed medical
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-directed medical therapies (ACE inhibitors, ARBs, β blockers, MRAs) at recommended doses
Trial: 30103979
Drug: Uptake of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uptake of guideline-directed medical therapies
Trial: 30464579
Drug: duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: duloxetine 60 mg/day
Trial: 30105657
Drug: Micafungin (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin (treatment for at least 1 week)
Trial: 30105657
Drug: Micafungin (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin (treatment for less than 1 week)
Trial: 30105657
Drug: Micafungin (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin (daily dose 50-100 mg)
Trial: 30105657
Drug: Micafungin (other
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin (other daily doses)
Trial: 30105951
Drug: Buparlisib, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib, 100 mg daily
Trial: 30106639
Drug: Serum biomarker
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum biomarker signature derived from a case-control study using an antibody microarray platform.
Trial: 30107868
Drug: C1-esterase inhibitor
RxNorm normalized name: HUMAN C1-ESTERASE INHIBITOR
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1-esterase inhibitor (C1-INH) 40 IU/kg twice weekly
Trial: 30107868
Drug: C1-esterase inhibitor
RxNorm normalized name: HUMAN C1-ESTERASE INHIBITOR
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1-esterase inhibitor (C1-INH) 60 IU/kg twice weekly
Trial: 30108004
Drug: Proton beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton beam radiation therapy (PRT)
Trial: 30109845
Drug: Aripiprazole lauroxil
RxNorm normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aripiprazole lauroxil 882 mg intramuscular every 4 weeks
Trial: 30109845
Drug: Aripiprazole lauroxil
RxNorm normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aripiprazole lauroxil 441 mg intramuscular every 4 weeks
Trial: 30109845
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with aripiprazole lauroxil
Trial: 30109845
Drug: Initial injections
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial injections of aripiprazole lauroxil
Trial: 30110589
Drug: Ibalizumab (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibalizumab (2000 mg loading dose, then 800 mg every 14 days)
Trial: 30111186
Drug: No second-generation
RxNorm normalized name: Second-generation cephalosporins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No second-generation antipsychotic exposure
Trial: 30115015
Drug: Monthly income
RxNorm normalized name: Lincomed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly income level < $1500
Trial: 30115015
Drug: Monthly income
RxNorm normalized name: Lincomed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly income level $1500-4500
Trial: 30115015
Drug: Monthly income
RxNorm normalized name: Lincomed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly income level > $4500 (reference)
Trial: 30115541
Drug: Cladribine plus
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine plus low-dose cytarabine alternating with decitabine for up to 18 cycles (induction therapy: cladribine 5 mg/m²).
Trial: 30115541
Drug: Cladribine plus
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine plus low-dose cytarabine alternating with decitabine.
Trial: 30115596
Drug: Bendamustine (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine (70 mg/m²) followed by obinutuzumab and venetoclax
Trial: 30115734
Drug: Itacitinib 300
RxNorm normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itacitinib 300 mg plus chemotherapy
Trial: 30117149
Drug: Rituximab 375
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m² weekly for 4 cycles
Trial: 30117149
Drug: Bendamustine (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine (specific dosage not mentioned)
Trial: 30119925
Drug: Adjuvant systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant systemic therapy (received by 402 patients, 48.4%)
Trial: 30120161
Drug: Regorafenib administered
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib administered daily for 3 weeks of each 4-week cycle until disease progression or other reason.
Trial: 30120518
Drug: AbobotulinumtoxinA (Dysport)
RxNorm normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: AbobotulinumtoxinA (Dysport) injection cycles
Trial: 30120956
Drug: Wet heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wet heparin suction
Trial: 30120956
Drug: Dry heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry heparin suction
Trial: 30120956
Drug: Dry heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry heparin
Trial: 30121602
Drug: Dabrafenib in
RxNorm normalized name: Product containing dabrafenib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabrafenib in combination with trametinib
Trial: 30121602
Drug: Dabrafenib monotherapy
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib monotherapy or combination therapy
Trial: 30121827
Drug: Secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 150 mg with loading dose
Trial: 30121827
Drug: Secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 150 mg without loading dose
Trial: 30121938
Drug: Short-course radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course radiotherapy (RT) at a maximum tolerated dose (MTD) of 20 Gy delivered in 2 days, twice daily.
Trial: 30122202
Drug: EORTC QLQ-C30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer-Core Quality of Life Questionnaire, version 3.0); range 0-100